Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$6.88 -0.82%

-$0.17 today

Market cap
$284.49M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.60M

Average 0.38M

EVMN Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Evommune, Inc.NYSE: EVMN

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow grows 15.4% year over year

Q1 FY2026 free cash flow of $27.59M (cash outflow) rose 15.4% year over year. Sequentially, it rose 64.2% from the prior quarter.

Context

  • Free cash flow amounted to 589.8% of revenue in FY2025, down 242.8 pp from a year earlier.
  • Free cash flow grew in size in 2 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$27.59M+64.2% QoQ
Last fiscal yearDec 2025
-$76.68M+31.6% YoY
LTMMar 2026
-$80.36M— YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.4%——
1 year+31.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(76.68M) USD
Year-over-year change
-31.6%

Free Cash Flow vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 free cash flow of $80.36M is the 5th largest of the 10 companies compared; the peer median is $53.49M.
  • Free cash flow amounts to 803.6% of revenue for EVMN, versus a peer median of 42.2%.
EVMN Competitors Peer median
Free Cash Flow for EVMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$271.54M +79.5%+53.6%3565.9%
FTREFortrea Holdings Inc.LTM Jun 2026$150.6M +246.1%+46.1%5.6%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$131.37M +229.2%-25.8%45.2%
ZYMEZymeworks Inc.LTM Sep 2026$112.33M +69.7%—42.2%
EVMNEvommune, Inc.LTM Mar 2026$80.36M ——803.6%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$80.18M +31.6%+11.6%—
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$59.11M -51.8%-20.4%39.1%
CLYMClimb Bio, Inc.LTM Mar 2026$53.49M +83.3%+13.4%—
OABIOmniAb, Inc.LTM Mar 2026$26.02M -34.4%+21.3%90.0%
CDXSCodexis, Inc.LTM Mar 2026$22.12M -63.0%—28.3%
Peer median (excluding EVMN) $53.49M+69.7%+13.4%42.2%

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.05M)(66.81M)(68.87M)
Depreciation & Amortization1M1.29M1.39M
Deferred Income Tax000
Stock-Based Compensation000
Change in Working Capital3.34M7.42M(4.12M)
Accounts Receivables000
Inventory000
Accounts Payables125K6.51M(837K)
Other Working Capital3.22M918K(3.28M)
Other Non-Cash Items(261K)(98K)(4.84M)
Operating Cash Flow(29.97M)(58.2M)(76.44M)
Capital Expenditures(118K)(88K)(235K)
Acquisitions (Net)000
Purchases of Investments(91.31M)(90.26M)(199.17M)
Sales of Investments43M86.35M84.1M
Other Investing Activities000
Investing Cash Flow(48.43M)(3.99M)(115.31M)
Debt Repayment00(373K)
Common Stock Issued63.98M49.84M222.36M
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities(230K)(423K)(1.22M)
Financing Cash Flow63.75M49.42M220.76M
Effect of Forex Changes43.67M(1)(1.21M)
Net Change in Cash29.02M(12.77M)27.81M
Free Cash Flow(30.09M)(58.28M)(76.68M)

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$6.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.